VAIA
BSTC

Virtus Alternative Investment Advisers’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-165
Closed -$9K – 274
2019
Q4 		$9K Buy
+165
New +$8.75K 0.14% 220

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Virtus Alternative Investment Advisers's BSTC Position: Q1 2020 in Review

Virtus Alternative Investment Advisers sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2020, closing a stake of 165 shares — an estimated $9K sold.

Virtus Alternative Investment Advisers first reported a position in BSTC in Q4 2019 and held it in 1 quarter. The position peaked at $9K in Q4 2019. 113 funds tracked by Wall St. Rank hold BSTC as of Q1 2020.

  • Virtus Alternative Investment Advisers reported no remaining BioSpecifics Technologies Corp. position as of Q1 2020 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 165 BioSpecifics Technologies Corp. shares in Q1 2020, an estimated $9K.
  • Virtus Alternative Investment Advisers first reported a position in BioSpecifics Technologies Corp. in Q4 2019 and held it in 1 quarter.
  • Virtus Alternative Investment Advisers's BioSpecifics Technologies Corp. position peaked at $9K in Q4 2019.
  • 113 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2020.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2020, filed 15 May 2020.